Asieris to Start US Combination Trial of MetAP2 Inhibitor for Bladder Cancer
June 15, 2021 at 04:49 AM EDT
Asieris Pharma of Shanghai has been approved to start US trials of its MetAP2 inhibitor in patients with muscle invasive bladder cancer (MIBC). APL-1202 is an oral reversible MetAP2 inhibitor with anti-angiogenic, anti-tumor activities that is also believed to modulate the tumor immune microenvironment. The MetAP2 inhibitor will be administered along with BeiGene's approved anti-PD-1 drug, tislelizumab. Asieris plans to accelerate patient enrollment in the US while it also files a Clinical Trial Application in China . More details.... Share this with colleagues: // //
